The
question, "Should statins be in your medicine cabinet?'"
has stirred up controversy and initiated debates among doctors and
drug companies.
More Red Flags Raised Over Statins
-
Bayer's statin, Baycol, was pulled from the market in 2001
after 31 deaths were reported from a harmful side effect of
the drug known as rhabdomyolysis, a condition in which muscle
tissue breaks down and could result in kidney failure.
-
Doctors recommended taking AstraZenica's Crestor off the market
after cases of rhabdomyolysis surfaced in trials of people taking
80-milligram doses
-
The FDA turned down the requests for over the counter prescriptions
for Mevachor and Pravachol stating there wasn't enough documentation
that the drugs were safe to take without a doctor's supervision.
-
Other experts stated that non-prescription statins were not
a good idea because of all of the variables that needed to be
taken into account such as possible health risks and benefits
before a person decided to take them
One doctor explained that the statins worked by preventing the
formation of cholesterol and that it helped reduce LDL cholesterol,
which is considered the "bad" cholesterol. Past studies
on statins have shown that they had the ability to lower the levels
of C-reactive protein, a substance found in the blood that acts
as an indicator of inflammation and heart disease.
What Statin Supporters Had to Say
-
A spokesperson for AstraZenica discounted those who wanted
Crestor removed from shelves and claimed that it was just as
safe as other statins They also claimed that it was the hardest
working statin in terms of decreasing LDL cholesterol levels
-
The first over-the-counter statin, simvastatin (Zocor), will
be available in the United Kingdom toward the end of summer
-
Merck spokesman is once again pushing for the sales of an over-the-counter
statin called Mevachor, a 20-milligram statin
USA
Today June 28, 2004
|